The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
TCL
Vol.
37
No.
21
May 27, 2011
CCL
Vol.
34
No.
5
May 27, 2011
- ASCO Highlights Seven of 4,000 Abstracts Submitted for Annual Meeting, June 3-7
- Analyzing Tumor Tissue In Clinical Trials Can Improve Outcomes, RTOG Trial Finds
- Targeting One Specific Protein Can Double PFS; Triple Overall Survival
- Revlimid Maintenance Therapy Delayed Progression by 90%
- Drug Effectiveness Weakens After Three Years, Study Says
- Nexavar Improves PFS In HER-2 Negative Breast Cancer
- Xgeva Significantly Increases Bone Metastasis-Free Survival
- U.S. Patients Use More Chemotherapy, Less Emergency Care than Canadians
- Urocidin May Provide Alternative To Cystectomy in BCG Cancers
- Clinical Trials Approved By NCI CTEP Last Month
- Afinitor and Sutent Approved For Pancreatic Neuroendocrine Tumors
- Abbott PCR Test For HCV Load Sensitive to Within 12 IU/mL
TCL
Vol.
37
No.
24
June 17, 2011
- Three Venerable Acronyms Fade Away As Cooperative Groups Form “Alliance”
- ASCO Urges NCI To Spell Out Metrics of Success Beyond Cutting Groups to Arbitrary Number
- Former NCI, FDA Chief Andrew Von Eschenbach Appointed to NCCN Foundation Board
- GAO Decision Clears NCI to Deploy Medidata Rave Data Capture System
- FDA Updates Safety Information for 5-Alpha Reductase Inhibitors
- ACS Report Says Drop in Cancer Mortality Saved 898,000 Lives Over 17 Years
- Stand Up To Cancer Co-Founder Laura Ziskin Dies of Complications From Breast Cancer at 61
TCL
Vol.
37
No.
25
June 24, 2011
- BSA Approves Provocative Questions RFA; NCI Announces Review of SAIC-Frederick, for caBIG Restructuring
- Henschke: I-ELCAP Plans to Enroll 100,000 Patients In Controversial Screening Trial
- Guest Editorial: Richard Schilsky Reflects On His Past Decade WithThe Board of Scientific Advisors
- I-ELCAP Results Internally Inconsistent, Peter Bach Writes
CCL
Vol.
34
No.
6
June 24, 2011
- NCI Lung Cancer Mutation Consortium: Screening For Mutations Can Focus Therapy
- Two Trials Presented at ASCO Demonstrate Drop in Death Risk, Increased Survival
- OCEANS Study: Avastin Shows Tumor Shrinkage in 79 Percent
- Cetuximab Plus Chemoradiation Boosts Survival in Phase II Study
- First-Line Tarceva Nearly Doubles PFS in EGFR-Activated Tumors
- Telatinib Demonstrates Positive Results in First-Line Treatment
- Barret’s Less of a Risk Factor For Cancer of the Esophagus
- New Abiraterone Acetate Results Show Greater Benefit Than Before
- MGMT Gene Can Determine Disease Aggressiveness
- Phase III Study: Lymphoseek Superior to Vital Blue Dye
- Intensity Modulated Therapy Safer Than Three-Dimensional Radiation
- Smokers Quitlines Found Effective Regardless of Recruitment Method
- Study: Vismodegib Effective Where Surgery is Inappropriate
- NCI-Approved Clinical Trials For The Month of June
- FDA: Silicone Breast Implants Safe, But Not “Lifetime Device”
- FDA Updates Safety Labeling Of 5-Alpha Reductase Inhibitors